News

The Manila Times31m
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
On May 7, 2025, Y-mAbs announced that naxitamab-gqgk (DANYELZA ®) has been recommended by the National Comprehensive Cancer Network ® ("NCCN”) Clinical Practice Guidelines in Oncology (NCCN Guidelines ...
Skye Bioscience Clinical Model Demonstrating Necessity Of Peripheral CB1 Inhibition For Weight Loss Presented At European Congress On Obesity
The poster can be accessed on Skye's Spotlight page .